A new trading day began on Tuesday, with Enanta Pharmaceuticals Inc (NASDAQ: ENTA) stock price down -3.78% from the previous day of trading, before settling in for the closing price of $5.03. ENTA’s price has ranged from $4.87 to $17.80 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -19.00% over the past five years. Meanwhile, its annual earnings per share averaged 11.81%. With a float of $19.73 million, this company’s outstanding shares have now reached $21.19 million.
Let’s look at the performance matrix of the company that is accounted for 131 employees. In terms of profitability, gross margin is 98.13%, operating margin of -179.92%, and the pretax margin is -174.15%.
Enanta Pharmaceuticals Inc (ENTA) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Enanta Pharmaceuticals Inc is 6.90%, while institutional ownership is 100.36%. The most recent insider transaction that took place on Dec 06 ’24, was worth 18,401. In this transaction Chief Product Strategy Officer of this company sold 2,283 shares at a rate of $8.06, taking the stock ownership to the 29,305 shares. Before that another transaction happened on Dec 06 ’24, when Company’s Chief Business Officer sold 2,283 for $8.06, making the entire transaction worth $18,401. This insider now owns 36,047 shares in total.
Enanta Pharmaceuticals Inc (ENTA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 11.81% per share during the next fiscal year.
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Trading Performance Indicators
Here are Enanta Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.49, a number that is poised to hit -1.35 in the next quarter and is forecasted to reach -4.69 in one year’s time.
Technical Analysis of Enanta Pharmaceuticals Inc (ENTA)
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) saw its 5-day average volume 0.79 million, a positive change from its year-to-date volume of 0.77 million. As of the previous 9 days, the stock’s Stochastic %D was 10.00%. Additionally, its Average True Range was 0.45.
During the past 100 days, Enanta Pharmaceuticals Inc’s (ENTA) raw stochastic average was set at 0.01%, which indicates a significant decrease from 0.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 24.57% in the past 14 days, which was lower than the 58.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.99, while its 200-day Moving Average is $11.80. Nevertheless, the first resistance level for the watch stands at $5.00 in the near term. At $5.17, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.25. If the price goes on to break the first support level at $4.76, it is likely to go to the next support level at $4.68. Assuming the price breaks the second support level, the third support level stands at $4.51.
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Key Stats
With a market capitalization of 102.58 million, the company has a total of 21,194K Shares Outstanding. Currently, annual sales are 67,640 K while annual income is -116,050 K. The company’s previous quarter sales were 14,610 K while its latest quarter income was -28,820 K.
